Endometrial Cancer: State-of-the-Art and Clinical Perspective

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Obstetrics & Gynecology".

Deadline for manuscript submissions: 25 September 2024 | Viewed by 1827

Special Issue Editor


E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, University Campus Biomedico of Rome, Rome, Italy
Interests: surgical oncology; screening; laparoscopic surgery laparoscopic; urinary incontinence; oncology; laparoscopy; gynecologic oncology

Special Issue Information

Dear Colleagues,

Endometrial carcinoma is the most common gynecologic malignancy, and the incidence of endometrial carcinoma is estimated to increase by 1–2% every year. Treatment modalities in endometrial cancer vary depending on the grade and the stage of the disease. In recent years, sentinel lymph node (SLN) sampling has been advocated as an alternative to standard hysterectomy with complete lymphadenectomy. Surgery is the standard treatment for early-stage endometrial cancer. Additional treatment, depending on the stage of the disease, may include radiation with or without chemotherapy, hormone therapy, immunotherapy, and some targeted therapies. Several new treatments for advanced disease have become available. Determining the molecular subtypes of cancers and deciding treatment according to type have both impacted practice. Other advances in this field include the use of immunotherapy and targeted therapies. This Special Issue aims to report the last advancements regarding the current understanding of endometrial cancer, including genetic background, molecular targeting, surgical management, and adjuvant treatment.

Dr. Francesco Plotti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endometrial cancer
  • sentinel node
  • immounotherapy
  • target therapies
  • hormone therapy

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 1354 KiB  
Article
Predictive Role of Pre-Operative Anemia in Early Recurrence of Endometrial Cancer: A Single-Center Study in Romania
by Mihaela Ionică, Marius Biris, Florin Gorun, Nicoleta Nicolae, Zoran Laurentiu Popa, Maria Cezara Muresan, Marius Forga, Dragos Erdelean, Izabella Erdelean, Mihai Adrian Gorun and Octavian Constantin Neagoe
J. Clin. Med. 2024, 13(3), 794; https://doi.org/10.3390/jcm13030794 - 30 Jan 2024
Viewed by 728
Abstract
This study aims to investigate the association between anemia and early recurrence in endometrial cancer patients. We retrospectively analyzed the data of 473 endometrial cancer patients treated at our hospital from January 2015 to December 2020. Patients were divided into two groups based [...] Read more.
This study aims to investigate the association between anemia and early recurrence in endometrial cancer patients. We retrospectively analyzed the data of 473 endometrial cancer patients treated at our hospital from January 2015 to December 2020. Patients were divided into two groups based on their hemoglobin (Hb) level: anemia group (Hb < 12 g/dL) and non-anemia group (Hb ≥12 g/dL). Early recurrence was defined as recurrence within 2 years of diagnosis. Univariate and multivariate logistic regression analyses were used to identify the predictors of early recurrence. The prevalence of anemia was 38.26% (181/473). The incidence of early recurrence was 12.89% (61/473) in the anemia group and 9.24% (38/412) in the non-anemia group (p = 0.004). Univariate analysis showed that anemia was a significant predictor of early recurrence (odds ratio (OR) = 2.27, 95% confidence interval (CI): 1.35–3.80, p = 0.003). Multivariate analysis confirmed that anemia was an independent predictor of early recurrence (OR = 2.11, 95% CI: 1.21–3.84, p = 0.01). Anemia is an independent predictor of early recurrence in endometrial cancer patients. Patients with endometrial cancer should be screened for anemia and treated if present. Additionally, patients with anemia should be closely monitored for early signs of recurrence and treated aggressively. Full article
(This article belongs to the Special Issue Endometrial Cancer: State-of-the-Art and Clinical Perspective)
Show Figures

Figure 1

11 pages, 594 KiB  
Article
Impact of COVID-19 Pandemic on the Diagnostic and Therapeutic Management of Endometrial Cancer: A Monocentric Retrospective Comparative Study
by Francesco Plotti, Adele Silvagni, Roberto Montera, Carlo De Cicco Nardone, Daniela Luvero, Fernando Ficarola, Gianna Barbara Cundari, Francesco Branda, Roberto Angioli and Corrado Terranova
J. Clin. Med. 2023, 12(22), 7016; https://doi.org/10.3390/jcm12227016 - 09 Nov 2023
Viewed by 877
Abstract
Endometrial cancer represents an ideal target to evaluate the impact of COVID-19 being the most frequent gynecological malignancy in Italy, generally detected at early stages and correlated with favorable oncological outcomes. The present comparative retrospective study carried out at Campus Bio-medico University Foundation [...] Read more.
Endometrial cancer represents an ideal target to evaluate the impact of COVID-19 being the most frequent gynecological malignancy in Italy, generally detected at early stages and correlated with favorable oncological outcomes. The present comparative retrospective study carried out at Campus Bio-medico University Foundation in Rome aims to evaluate the impact of the COVID-19 pandemic on the presentation, diagnosis and treatment of EC. All women with a histological diagnosis of non-endometrioid and endometrioid endometrial cancer between 1 March 2018 and 31 October 2022 were included. The number of cases was higher in period 2 (95 vs. 64 cases). Time to diagnosis did not show statistically significant differences but in period 2, 92.06% of the diagnoses were made following abnormal uterine bleeding, while in period 1, only 67.02% were. The waiting time for the intervention was significantly shorter in period 2. Definitive histology, FIGO staging, surgical technique and adjuvant therapy did not show significant differences between the two periods. The study demonstrates that the impact of the COVID-19 pandemic did not have a direct effect on the diagnostic delay, tumor staging and type of therapy but rather on the presentation pattern of endometrial cancer. Full article
(This article belongs to the Special Issue Endometrial Cancer: State-of-the-Art and Clinical Perspective)
Show Figures

Figure 1

Back to TopTop